Why the study?
Calcific aortic valve disease prevalence is increasing, but effective means to delay or reverse its progression are lacking.
Does PARM1 knockdown prevent osteogenic differentiation and aortic valve calcification in preclinical models?
Does PARM1 knockdown prevent osteogenic differentiation and aortic valve calcification in preclinical models?
PARM1 knockdown mitigates aortic valve calcification via the PRKCH-MAPK signaling pathway, suggesting it may be a potential therapeutic target for calcific aortic valve disease.
Answers are grounded in this paper and cite their sources.
PARM1 may be a novel CAVD target; hypothesis-generating and should not yet change practice.
With the aging of the population, the prevalence of calcific aortic valve disease (CAVD) has increased yearly. However, effective means to delay or even reverse the progression of CAVD are still lacking. This study revealed that prostate androgen-regulated mucin-like protein 1 (PARM1) expression was significantly up-regulated in calcified aortic valve tissues. Functional investigations demonstrated that PARM1 knockdown effectively suppressed osteogenic differentiation of valvular interstitial cells (VICs) and mitigated pathological aortic valve calcification. Mechanically, PARM1 knockdown down-regulated PRKCH mRNA expression, consequently attenuating MAPK pathway activation during the osteogenic differentiation of VICs. In conclusion, PARM1 could be a feasible target for CAVD prevention.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: